M&A Reporting, CTFN

Jonathan Spitzer

M&A Reporting

CTFN

Bringing the marketplace leading coverage of mergers, events, and major corporate actions, CTFN has a team of seasoned reporters from Los Angeles to London, publishing news that advances stories that matter to event-driven investors and deal professionals.

Event-Driven

<p>On April 4, CVS Health announced a new initiative focused on chronic kidney disease with a planned introduction of “a truly innovative new home hemodialysis technology.” Experts applauded the news and said CVS’s entry into the space could be the biggest disruption to the dialysis market in the last 10-15 years.</p>

On April 4, CVS Health announced a new initiative focused on chronic kidney disease with a planned introduction of “a truly innovative new home hemodialysis technology.” Experts applauded the news and said CVS’s entry into the space could be the biggest disruption to the dialysis market in the last 10-15 years.

NxStage/Fresenius FTC Review Could Be Helped by Recent CVS Announcement

United States

NxStage Medical, Inc. is medical device company that develops, manufactures, and markets systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. The Company's primary product, the NxStage System One, is a small, portable hemodialysis system.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Nxstage Medical (NXTM US)

NxStage/Fresenius FTC Review Could Be Helped by Recent CVS Announcement

On April 4, CVS Health announced a new initiative focused on chronic kidney disease with a planned introduction of “a truly innovative new home...

CTFN

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)